HOMOCYSTEINEMIA STUDY
同型半胱氨酸血症研究
基本信息
- 批准号:6270399
- 负责人:
- 金额:$ 9.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-02-21 至 1998-11-30
- 项目状态:已结题
- 来源:
- 关键词:acquired aminoacid metabolism disorder bioassay cardiovascular disorder clinical research disease /disorder etiology disease /disorder proneness /risk genetic techniques histocompatibility homocysteine human subject human therapy evaluation kidney function kidney transplantation metabolism disorder chemotherapy metabolism disorder diagnosis methionine nutrition
项目摘要
Cardiovascular death and morbidity continue to be major long-term
complications in renal transplant patients. Abnormalities in lipids and
lipoproteins may partially contribute to the increased risk; however,
other risk factors may be involved. Homocysteine is rapidly emerging as an
important risk factor for the development of coronary, carotid and
peripheral atherosclerotic events. There is early evidence that elevated
homocysteine levels commonly occur in patients with renal transplants or
chronic renal disease, but the appropriate diagnostic or therapeutic
approaches have not been established.
The proposed studies include:
1.) The frequency and severity of hyper-homocysteinemia and the
appropriate diagnostic approach will be evaluated.
2.)The causes of hyper-homocysteinemia will be evaluated. They will
include the influence of renal function, nutritional, genetic and
concomitant medication.
3.) Therapeutic approaches to normalize both fasting and post-methionine
load homocysteine levels will be evaluated.
4.) The overall goal will be to develop simple clinical algorithms for the
diagnosis and treatment of homocysteine disorders.
心血管死亡和发病率仍然是主要的长期
肾移植患者的并发症脂质和
脂蛋白可能部分导致风险增加;然而,
可能涉及其他风险因素。同型半胱氨酸正在迅速成为一种
冠状动脉、颈动脉和
外周动脉粥样硬化事件。有早期证据表明,
同型半胱氨酸水平通常发生在肾移植患者或
慢性肾脏疾病,但适当的诊断或治疗
方法尚未确立。
拟议的研究包括:
1.)的人。高同型半胱氨酸血症的发生率和严重程度以及
将评估适当的诊断方法。
2.)的情况。将评价高同型半胱氨酸血症的原因。他们将
包括肾功能、营养、遗传和
合并用药。
3.)第三章使空腹和蛋氨酸后恢复正常的治疗方法
将评价负荷高半胱氨酸水平。
4.)总体目标将是开发简单的临床算法,
同型半胱氨酸疾病的诊断和治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DONALD B HUNNINGHAKE其他文献
DONALD B HUNNINGHAKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DONALD B HUNNINGHAKE', 18)}}的其他基金
HOMOCYSTEINE AS RISK FACTOR FOR CARDIOVASCULAR DISEASE IN RENAL TRANSPLANTATION
同型半胱氨酸是肾移植中心血管疾病的危险因素
- 批准号:
6264841 - 财政年份:1998
- 资助金额:
$ 9.63万 - 项目类别:
PROSPECTIVE RANDOMIZED EVALUATION OF THE VASCULAR EFFECTS OF NORVASC TRIAL
NORVASC 试验的血管效应的前瞻性随机评估
- 批准号:
6248198 - 财政年份:1997
- 资助金额:
$ 9.63万 - 项目类别:
PROSPECTIVE RANDOMIZED EVALUATION OF THE VASCULAR EFFECTS OF NORVASC TRIAL
NORVASC 试验的血管效应的前瞻性随机评估
- 批准号:
6278258 - 财政年份:1997
- 资助金额:
$ 9.63万 - 项目类别:
LIPID ABNORMALITIES IN CARDIOVASCULAR MORBIDITY IN RENAL TRANSPLANT RECIPIENTS
肾移植受者心血管疾病中的脂质异常
- 批准号:
6238645 - 财政年份:1997
- 资助金额:
$ 9.63万 - 项目类别:
POST CORONARY BYPASS GRAFT (CABG) STUDIES--AN NIH MULTICENTER TRIAL
冠状动脉搭桥术后 (CABG) 研究 - NIH 多中心试验
- 批准号:
6248155 - 财政年份:1997
- 资助金额:
$ 9.63万 - 项目类别:
相似国自然基金
ITS-HPLC-HRMS-Bioassay多级筛选策略指导下海洋真菌中新型抗菌活性产物的发现
- 批准号:41606166
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of advanced bioassay analysis system for internal dose assessment
开发用于内部剂量评估的先进生物测定分析系统
- 批准号:
23H03142 - 财政年份:2023
- 资助金额:
$ 9.63万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
This service is for The BPN Biologics program requires bioassay development expertise in order to support active cooperative agreements for drug development and discovery.
该服务适用于 BPN Biologics 计划需要生物测定开发专业知识,以支持药物开发和发现的积极合作协议。
- 批准号:
10949343 - 财政年份:2023
- 资助金额:
$ 9.63万 - 项目类别:
Development of a three-dimensional microkidney model and its disease model for bioassay
用于生物测定的三维微肾脏模型及其疾病模型的开发
- 批准号:
23H01983 - 财政年份:2023
- 资助金额:
$ 9.63万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a non-hormonal contraceptive antibody
开发合格的药代动力学生物测定法以支持非激素避孕抗体 MM-008 的临床前和临床研究
- 批准号:
10459074 - 财政年份:2022
- 资助金额:
$ 9.63万 - 项目类别:
Development of rapid and sensitive bioassay methods to contribute to actinide internal exposure medical response
开发快速、灵敏的生物测定方法,有助于锕系元素内照射医疗反应
- 批准号:
22K12384 - 财政年份:2022
- 资助金额:
$ 9.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of simple bioassay for detection of environmental trace contaminants and demonstration in Asian countries
开发用于检测环境痕量污染物的简单生物测定法并在亚洲国家进行示范
- 批准号:
21H01577 - 财政年份:2021
- 资助金额:
$ 9.63万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
L2M Market Assessment Grant: a bioassay to predict birth timing.
L2M 市场评估补助金:预测出生时间的生物测定。
- 批准号:
571251-2022 - 财政年份:2021
- 资助金额:
$ 9.63万 - 项目类别:
Idea to Innovation